2015-08-13T14:03:20-05:00 2014-12-31 221430039 SOBEL AND CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2014-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2015-08-12 1 BRIDGET HARTNETT P01429163 9739949494 2015-08-12 2014 2016-02-25 16:41:14Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 1453086 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY SOLVING KIDS' CANCER FINDS, FUNDS, AND MANAGES CLINICAL RESEARCH TRIALS TO FACILITATE THE DEVELOPMENT OF MORE EFFECTIVE AND LESS TOXIC TREATMENTS FOR THE DEADLIEST CHILDHOOD CANCERS. 100 % OF PUBLIC DONATIONS ARE USED FOR PROGRAM AND RESEARCH SUPPORT GRANTS. 6 5 5 0 0 0 743573 1381381 0 0 7027 5638 -118356 -135453 632244 1251566 449622 477288 0 0 443499 468256 0 0 166182 223178 262522 1116299 1208066 -484055 43500 3041656 3170173 4713 89730 3036943 3080443 X SOLVING KIDS' CANCER FINDS, FUNDS, AND MANAGES CLINICAL RESEARCH TRIALS TO FACILITATE THE DEVELOPMENT OF MORE EFFECTIVE AND LESS TOXIC TREATMENTS FOR THE DEADLIEST CHILDHOOD CANCERS. 100 % OF PUBLIC DONATIONS ARE USED FOR PROGRAM AND RESEARCH SUPPORT GRANTS. 0 0 846310 477288 SKC ACTIVELY FUNDS AND MANAGES INNOVATIVE CLINICAL RESEARCH PROGRAMS, FOCUSING ON AGGRESSIVE CHILDHOOD CANCERS WITH LOW SURVIVAL RATES. THE CLINICAL TRIALS THAT SKC FUNDS ARE DESIGNED TO ACCELERATE NEW, NEXT-GENERATION TREATMENTS FOR CHILDREN ALIVE TODAY, INCLUDING IMMUNOTHERAPY, CANCER VACCINES, AND NEW DRUGS, ALL WITH THE GOAL OF IDENTIFYING MORE EFFECTIVE AND LESS TOXIC CURATIVE PATHS FOR THE FUTURE. OVER THE LAST 8 YEARS, SKC HAS HELPED BRING 19 CLINICAL TRIALS TO CHILDREN WITH 18 NEW TREATMENT OPTIONS MADE AVAILABLE. THE RESEARCH PROJECTS SKC FUNDED IN 2014 INCLUDE: A PHASE I CLINICAL TRIAL OF COMBINATION IMMUNOTHERAPY USING HAPLOIDENTICAL NATURAL KILLER CELLS AND HU14.18-IL2 ANTIBODY FOR NEUROBLASTOMA; A PILOT STUDY OF PEPTIDE THERAPEUTIC VACCINE FOR RECURRENT EPENDYMOMAS; A PHASE I STUDY OF INTRA-ARTERIAL CHEMOTHERAPY FOR THE TREATMENT OF PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG); THE DEVELOPMENT OF A THERAPEUTIC ALK ANTIBODY FOR NEUROBLASTOMA; A PHASE I CLINICAL TRIAL OF COMBINATION IMMUNOTHERAPY USING 3RD-GEN GD2 T-CELL CARS PLUS PD1 INHIBITOR PEMBROLIZUMAB FOR NEUROBLASTOMA; THE DEVELOPMENT OF A PRECISION MEDICINE GENOMICS-MATCHED PILOT TRIAL FOR NEUROBLASTOMA; A PILOT STUDY OF THERAPEUTIC HIGH-INTENSITY FOCUSED ULTRASOUND (MR-HIFU) FOR HIGH-RISK NEUROBLASTOMA; A PHASE 1 CLINICAL TRIAL OF PD1 INHIBITOR NIVOLUMAB FOR HIGH-RISK BRAIN TUMORS; AND IMMUNE RESPONSE ASSAYS FOR OSTEOSARCOMA IN THE PHASE I//II TRIAL OF ACTIVATED T-CELLS ARMED WITH HUMANIZED 3F8 BISPECIFIC ANTIBODIES. 846310 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 11 0 1 5 1 0 0 0 0 0 1 1 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 200000 0 26686 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 CATHERINE LONDON DIRECTOR 2.00 X 0 0 0 ARI SPAR DIRECTOR 2.00 X 0 0 0 CHANNING STAVE SECRETARY 2.00 X X 0 0 0 200000 0 26686 1 0 1 0 0 607931 773450 1381381 5638 5638 66067 607931 201520 -135453 -135453 1251566 0 0 -129815 X 409688 409688 17600 17600 50000 50000 226686 181349 11334 34003 205765 72500 78848 54417 10601 2556 4972 3073 25204 13669 5849 5686 13600 13600 126055 68220 3791 54044 10082 10082 2064 2064 48186 27524 10588 10074 24136 3051 19378 1707 135 135 17427 17427 1570 1570 MEALS AND ENTERTAINMENT 8249 153 7595 501 PRINTING AND SHIPPING 4003 2458 1545 DATABASE EXPENSE 3288 3288 MISCELLANEOUS 2157 1025 1132 1570 1570 1208066 846310 195574 166182 259242 204268 2705119 2815988 5000 56954 67505 184524 110697 16756 73827 3585 3585 3041656 3170173 4713 39730 0 50000 4713 89730 X 2994943 2630631 42000 449812 3036943 3080443 3041656 3170173 43500 0 X X 0 1 X 1 0 X 706262 1047437 738702 309184 1381381 4182966 706262 1047437 738702 309184 1381381 4182966 423580 3759386 25234 15625 11123 7027 5638 64647 4247613 0.88510 0.80230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 3763 1397 179364 106934 72430 73827 REFUNDABLE ADVANCE 50000 50000 X 1251566 0 1251566 0 1251566 1208066 0 1208066 0 1208066 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2014 AND 2013. THE TAX YEARS SUBJECT TO AUDIT BY FEDERAL AND STATE JURISDICTIONS ARE THE YEARS ENDED DECEMBER 31, 2011 AND FORWARD. AT DECEMBER 31, 2014 AND 2013, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. 0 0 0 0 0 0 0 0 0 0 NORTH AMERICA PILOT STUDY OF MR-HIFU FOR HIGH-RISK NEUROBLASTOMA 50000 CHECK FMV 1 0 0 0 0 0 0 X X X X 0 ASTIC PRODUCTIONS 850 SEVENTH AVENUE NEW YORK NY 10019 ORGANIZATION OF SPRING CELEBRATION 0 665181 45854 619327 665181 45854 619327 SPRING CELEBRATION 665181 607931 57250 92873 105531 JUNIOR BOARD EVENT 4345 4345 2100 1 4472 4472 1016 673998 607931 66067 92873 108647 201520 -135453 SCHEDULE G, PART I, LINE 2B, COLUMN (V) PAYMENTS WERE MADE TO FUNDRAISER TO HELP ORGANIZE THE SPRING CELEBRATION 1 BOARD OF REGENTS- UNIVERSITY OF WISCONSIN 21 N PARK STREET SUITE 6401 MADISON WI 53715 396006492 501(C)(3) 30000 CASH CANCER RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3615 CIVIC CENTER BOULEVARD PHILADELPHIA PA 19104 231352166 501(C)(3) 100000 CASH CANCER RESEARCH BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 35000 CASH CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 242 GARLAND HALL BALTIMORE MD 21218 520595110 501(C)(3) 115341 CASH CANCER RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 42500 CASH CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 1650 ORLEANS STREET BALTIMORE MD 21231 520595110 501(C)(3) 36847 CASH CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 633 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 25000 CASH CANCER RESEARCH WAYNE STATE UNIVERSITY 5057 WOODWARD AVENUE DETRIOT MI 48202 383555142 501(C)(3) 25000 CASH CANCER RESEARCH SCIENTIFIC ADVISORY CONSULTING 1 17600 CASH PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 200000 0 0 0 0 0 0 0 26686 0 226686 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION A, LINE 2 JOHN LONDON AND CATHERINE LONDON ARE MARRIED. FORM 990, PART VI, SECTION B, LINE 11 THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND FORM 990 ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G BANK AND CREDIT CARD FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 2,416. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,416. MERCHANT FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 13,294. TOTAL EXPENSES 13,294. SCIENTIFIC CONSULTING: PROGRAM SERVICE EXPENSES 68,220. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 68,220. IT SUPPORT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 1,375. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,375. CONSULTING: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 12,750. TOTAL EXPENSES 12,750. PUBLIC RELATIONS : PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 28,000. TOTAL EXPENSES 28,000. FORM 990, PART XII, LINE 2C THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR.